Investigational Drug Information for AG-348
✉ Email this page to a colleague
What is the development status for investigational drug AG-348?
AG-348 is an investigational drug.
There have been 24 clinical trials for AG-348.
The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2023.
The most common disease conditions in clinical trials are Anemia, Hemolytic, Pyruvate Metabolism, Inborn Errors, and Anemia, Hemolytic, Congenital Nonspherocytic. The leading clinical trial sponsors are Agios Pharmaceuticals, Inc., National Heart, Lung, and Blood Institute (NHLBI), and National Institutes of Health Clinical Center (CC).
There are nine US patents protecting this investigational drug and one hundred and thirty-five international patents.
Summary for AG-348
| US Patents | 9 |
| International Patents | 135 |
| US Patent Applications | 23 |
| WIPO Patent Applications | 8 |
| Japanese Patent Applications | 2 |
| Clinical Trial Progress | Phase 3 (2023-06-01) |
| Vendors | 44 |
Recent Clinical Trials for AG-348
| Title | Sponsor | Phase |
|---|---|---|
| Safety and Efficacy of Mitapivat Sulfate in Adult Patients With Erythrocyte Membranopathies | EuroBloodNet Association | Phase 2 |
| A Study to Provide Continued Access to Mitapivat for Participants Who Previously Completed an Agios-Sponsored Mitapivat Study | Agios Pharmaceuticals, Inc. | Phase 4 |
| A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function | Agios Pharmaceuticals, Inc. | Phase 1 |
Clinical Trial Summary for AG-348
Top disease conditions for AG-348
Top clinical trial sponsors for AG-348
US Patents for AG-348
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| AG-348 | ⤷ Sign Up | Therapeutic compounds and compositions | Agios Pharmaceuticals, Inc. (Cambridge, MA) | ⤷ Sign Up |
| AG-348 | ⤷ Sign Up | Pyruvate kinase activators for use in therapy | Agios Pharmaceuticals, Inc. (Cambridge, MA) | ⤷ Sign Up |
| AG-348 | ⤷ Sign Up | Methods of using pyruvate kinase activators | Agios Pharmaceuticals, Inc. (Cambridge, MA) | ⤷ Sign Up |
| AG-348 | ⤷ Sign Up | Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfon- amide | Agios Pharmaceuticals, Inc. (Cambridge, MA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for AG-348
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| AG-348 | Argentina | AR077292 | 2029-06-29 | ⤷ Sign Up |
| AG-348 | Argentina | AR112803 | 2029-06-29 | ⤷ Sign Up |
| AG-348 | Australia | AU2010266386 | 2029-06-29 | ⤷ Sign Up |
| AG-348 | Brazil | BRPI1011587 | 2029-06-29 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
